

Claims

1. An adiponectin receptor expression-enhancing agent, comprising a FoxoI protein or a FoxoI gene.
2. An adiponectin resistance-improving agent, comprising a FoxoI protein or a FoxoI gene as an active ingredient.
3. An obesity-preventing or improving agent, comprising a FoxoI protein or a FoxoI gene as an active ingredient.
4. A diabetes-preventing or treating agent, comprising a FoxoI protein or a FoxoI gene as an active ingredient.
5. An arteriosclerosis-preventing or treating agent, comprising a FoxoI protein or a FoxoI gene as an active ingredient.
6. An adiponectin receptor expression-inducing agent, comprising an insulin signaling pathway inhibitor.
7. The adiponectin receptor expression-inducing agent of claim 6, wherein an insulin signaling pathway inhibitor is a Phosphoinositide 3 (PI3) -kinase inhibitor.
8. The adiponectin receptor expression-inducing agent of claim 7, wherein the Phosphoinositide 3 (PI3)-kinase inhibitor is LY294002.
9. An adiponectin resistance-improving agent, comprising as an active ingredient the adiponectin receptor expression-inducing agent of any one of claims 6 to 8.
10. An obesity-preventing or improving agent, comprising as an active ingredient the adiponectin receptor expression-inducing agent of any one of claims 6 to 8.
11. A diabetes-preventing or treating agent, comprising as an active ingredient the adiponectin receptor expression-inducing agent of any one of claims 6 to 8.

12. An arteriosclerosis-preventing or treating agent, comprising as an active ingredient the adiponectin receptor expression-inducing agent of any one of claims 6 to 8.
13. An adiponectin receptor expression-suppressing agent, comprising insulin or insulin gene.